RGNX PEER ANALYSIS

Regenxbio Inc — metric-by-metric comparison with peers and the industry median

RGNXRegenxbio Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

RGNXIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	RGNX	MSB	TLX	RTALB	CSL	Ind. Median
P/E	—	—	—	4.89●	30.02	17.81
P/B	36.88	—	6.56	0.61●	2.24	3.49
EV/EBITDA	—	—	123.31	74.61	10.37●	14.92
P/S	8.85	31.91	3.34	6.67	2.67●	10.89

Financial Health
Metric	RGNX	MSB	TLX	RTALB	CSL	Ind. Median
Current Ratio	2.62●	—	1.43	1.21	2.57	5.90
Debt/Equity	337.1%	—	112.3%	1.2%●	67.4%	10.9%
NetDebt/EBITDA	0.35●	—	13.13	0.90	2.22	1.15

Profitability
Metric	RGNX	MSB	TLX	RTALB	CSL	Ind. Median
Net Margin	-330.2%	-115.3%	-0.9%	136.3%●	9.2%	-125.7%
ROE	-196.4%	-11.3%	-1.8%	15.1%●	7.7%	-47.5%
ROA	-69.6%	-8.6%	-0.7%	13.1%●	3.8%	-35.8%
EBITDA Margin	-261.2%	-76.6%	3.0%	9.0%	32.8%●	-105.8%

Growth + Dividend
Metric	RGNX	MSB	TLX	RTALB	CSL	Ind. Median
Rev. Growth	-44.0%	410.4%●	56.3%	24.0%	4.8%	5.1%
NI Growth	—	—	—	134.0%●	-39.4%	12.1%
Div. Yield	—	0.0%	—	0.0%	2.5%●	0.2%
Payout	—	0.0%	—	0.0%	103.1%	0.0%

Valuation
Metric	RGNX	PRME	ACRS	XOMA	RIGL	DNA	Ind. Median
P/E	—	—	—	24.24	2.18●	—	17.81
P/B	36.88	9.21	4.92	6.77	1.98	1.36●	3.49
EV/EBITDA	—	—	—	15.82	5.27●	—	14.92
P/S	8.85	175.16	84.52	21.08	2.64●	4.26	10.89

Financial Health
Metric	RGNX	PRME	ACRS	XOMA	RIGL	DNA	Ind. Median
Current Ratio	2.62	3.80	4.03	3.59	2.62	5.15●	5.90
Debt/Equity	337.1%	149.3%	1.4%●	110.5%	11.4%	92.7%	10.9%
NetDebt/EBITDA	0.35	0.11	1.46	0.59	-0.77●	-0.18	1.15

Profitability
Metric	RGNX	PRME	ACRS	XOMA	RIGL	DNA	Ind. Median
Net Margin	-330.2%	-4,917.6%	-832.6%	87.0%	121.5%●	-215.4%	-125.7%
ROE	-196.4%	-216.1%	-48.4%	31.9%	174.1%●	-55.8%	-47.5%
ROA	-69.6%	-63.7%	-35.1%	13.0%	107.0%●	-26.2%	-35.8%
EBITDA Margin	-261.2%	-4,732.2%	-843.9%	138.4%●	43.8%	-149.2%	-105.8%

Growth + Dividend
Metric	RGNX	PRME	ACRS	XOMA	RIGL	DNA	Ind. Median
Rev. Growth	-44.0%	-90.3%	-52.9%	-3.3%	47.6%●	-40.5%	5.1%
NI Growth	—	—	—	—	879.7%	—	12.1%
Div. Yield	—	—	—	0.7%	—	—	0.2%
Payout	—	—	—	17.5%	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on RGNX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.